Report Highlights

Regulatory Affairs Outsourcing in the U.S.: Market Overview

The U.S. healthcare regulatory affairs outsourcing market was valued at USD 2.4 billion in 2024 and is anchored by the FDA's fee-funded review architecture. Sponsors outsource dossier preparation, establishment registration, labeling and post-market reporting because user fees under PDUFA and MDUFA fund FDA review staff but not sponsor-side compliance capacity. Private providers lead delivery, with IQVIA, Parexel and ICON plc dominating drug work and Emergo by UL Solutions prominent in devices.

Government has been the dominant force in shaping the market's form, since statutory user fees, 21 CFR Part 820 quality system rules and the 21 CFR Part 11 electronic records rule define exactly what outsourced work must deliver. The private sector leads on execution, with Medpace, Syneos Health and Freyr Solutions competing on speed, specialist depth and therapeutic expertise. Government sets the standard; private providers sell the capacity to meet it.

Policy-Driven Growth in U.S. Regulatory Affairs Outsourcing

PDUFA VII, the Prescription Drug User Fee Amendments covering FY2023 to FY2027, sets goal-date commitments of ten months for standard new molecular entity reviews. Sponsors that cannot staff submissions in-house buy dossier and deficiency-response support from providers, so each statutory review clock transfers workload to outsourcers. The mechanism is direct: fixed review deadlines convert into predictable outsourced demand.

The FD&C Act Section 524B cybersecurity mandate, enacted through the Consolidated Appropriations Act 2023, requires device makers to document software bills of materials and vulnerability management plans in premarket submissions. The 21st Century Cures Act of 2016 expanded real-world evidence pathways, obliging sponsors to structure post-market data programs. Both push specialist documentation work toward outsourcers with the capacity to produce it.

Regulatory Barriers and Compliance Costs in the United States

PDUFA application fees for FY2025 reached USD 4.3 million per full application containing clinical data, a sum administered by FDA's Center for Drug Evaluation and Research. Smaller sponsors absorb this cost before any outsourcing spend begins, which lengthens time-to-market. Foreign-based device sponsors face a further barrier: under 21 CFR 807.40 they must designate a U.S. agent, and missed registration renewals trigger import alerts enforced by FDA's Office of Regulatory Affairs.

HIPAA, administered by the HHS Office for Civil Rights, requires business associate agreements with every outsourcing vendor handling protected health information. Analyst estimates put negotiation and audit of these agreements at six to twelve weeks of added vendor onboarding time. State laws such as California's Consumer Privacy Act add parallel obligations for non-PHI data, enforced by the California Privacy Protection Agency.

Policy-Created Opportunities in U.S. Regulatory Affairs Outsourcing

FDA's Quality Management System Regulation, which amends 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, takes effect on February 2, 2026. Every medical device manufacturer must rebuild its quality documentation, creating a one-time remediation demand that outsourcers capture through gap assessments and procedure rewrites. Providers with ISO 13485 auditing credentials hold a direct advantage in this window.

FDA's January 2025 draft guidance on artificial intelligence for regulatory decision-making, alongside ICH E6(R3) good clinical practice adopted by FDA, creates demand for validated AI-assisted submission tooling and risk-based monitoring documentation. Providers with computer system validation capability under 21 CFR Part 11 can position these services ahead of competitors. Early adopters will secure multi-year contracts with sponsors facing the new standards.

Market at a Glance

Leading Market Participants

• IQVIA
• Parexel
• ICON plc
• Syneos Health
• Medpace
• Thermo Fisher Scientific
• Emergo by UL Solutions
• Freyr Solutions
• Certara
• Cognizant

Regulatory and Policy Environment for U.S. Healthcare Regulatory Affairs

The primary legislation is the Federal Food, Drug, and Cosmetic Act, administered by the FDA and supplemented by PDUFA VII and MDUFA V, whose fee authority expires on September 30, 2027. Key compliance requirements include 21 CFR Part 11 for electronic records, 21 CFR Part 820 for quality systems, and 21 CFR Part 807 for establishment registration and listing. The next major change is the PDUFA VIII reauthorization, which must pass Congress before that September 2027 deadline.

Compared with regional peers, the U.S. framework imposes stricter device cybersecurity documentation under Section 524B than the EU Medical Device Regulation (EU) 2017/745, which relies on notified body conformity assessment rather than a statutory SBOM mandate. Health Canada's fee structure is less intensive than the FDA's user fee architecture, and Japan's PMDA operates with a narrower agent accountability model. The U.S. therefore sets the most demanding documentation baseline in the region.

Long-Term Policy Outlook for U.S. Healthcare Regulatory Affairs

PDUFA VIII and MDUFA VI commitments will define FDA review performance from FY2028 onward. Fee-funded hiring at FDA will expand review capacity, reducing sponsor-side dossier rework and shifting outsourcing demand toward lifecycle work such as labeling changes, pharmacovigilance and post-market surveillance.

By 2032, full adoption of the QMSR, enforcement of Section 524B and validated AI tooling will reshape demand toward cybersecurity, data governance and AI-validated submissions. Providers without these capabilities will lose share to specialists such as Emergo by UL Solutions and Freyr Solutions, which already operate U.S.-based agent services.